Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection

SIMPLE SUMMARY: The introduction of immune checkpoint inhibitors (ICI) in 2011 revolutionized the management of many solid cancers and hematological malignancies. However, there are concerns regarding the use of ICI in the era of COVID-19. We present currently available information on the pros and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gambichler, Thilo, Reuther, Judith, Scheel, Christina H., Susok, Laura, Kern, Peter, Becker, Jürgen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698088/
https://www.ncbi.nlm.nih.gov/pubmed/33207589
http://dx.doi.org/10.3390/cancers12113383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698088/
https://www.ncbi.nlm.nih.gov/pubmed/33207589
http://dx.doi.org/10.3390/cancers12113383

Ejemplares similares